{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:15:32Z","timestamp":1779167732366,"version":"3.51.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatocellular carcinoma (HCC) is one of the most lethal malignancies with limited treatment options. Lenvatinib is a first-line drug for advanced HCC. However, its effect on patient survival is limited and patients ultimately develop disease progression due to drug resistance. In this study, we established a lenvatinib-resistant orthotopic xenograft model and found a significant upregulation of ANXA3. Further researches revealed that ANXA3 facilitated lenvatinib resistance in vitro and in vivo. Mechanistically, ANXA3 activated the PI3K pathway and enhanced the transcription of PDGF-AA, thus promoting tumor angiogenesis. Besides, ANXA3 also promoted EMT and autophagy through the PI3K pathway. These three effects were comprehensively responsible for the roles of ANXA3 in facilitating lenvatinib resistance. What\u2019s more, the secreted PDGF-AA could in turn activate the PI3K pathway, thus forming a positive feedback loop, which could amplify the effects driven by ANXA3. Alpelisib is a PI3K inhibitor approved for breast cancer treatment by FDA. We demonstrated that Alpelisib may synergistically improve the antitumor effects of lenvatinib without increasing side effects. This study reports ANXA3 as a biomarker o predict poor prognosis and lenvatinib resistance in HCC. The combined use of Alpelisib and lenvatinib may serve as a potential therapeutic strategy for lenvatinib-resistant HCC.<\/jats:p>","DOI":"10.1038\/s41419-026-08735-9","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T18:47:24Z","timestamp":1776106044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Annexin A3 potentiates lenvatinib resistance in hepatocellular carcinoma through multiple approaches amplified by a positive feedback loop"],"prefix":"10.1038","volume":"17","author":[{"given":"Yingqin","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengjia","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dijun","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaopin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qijing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5286-587X","authenticated-orcid":false,"given":"Tong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1268-3967","authenticated-orcid":false,"given":"Jianchuan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuzhong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"8735_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"8735_CR2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","volume":"150","author":"J Bruix","year":"2016","unstructured":"Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835\u201353.","journal-title":"Gastroenterology"},{"key":"8735_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345\u201362.","journal-title":"Lancet"},{"key":"8735_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"8735_CR5","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-13-0547","volume":"20","author":"JM Llovet","year":"2014","unstructured":"Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res. 2014;20:2072\u20139.","journal-title":"Clin Cancer Res"},{"key":"8735_CR6","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"8735_CR7","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","volume":"35","author":"B Sangro","year":"2024","unstructured":"Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024;35:448\u201357.","journal-title":"Ann Oncol"},{"key":"8735_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188391","volume":"1874","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer. 2020;1874:188391.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8735_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/638747","volume":"2014","author":"O Tohyama","year":"2014","unstructured":"Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747.","journal-title":"J Thyroid Res"},{"key":"8735_CR10","doi-asserted-by":"publisher","first-page":"e204930","DOI":"10.1001\/jamaoncol.2020.4930","volume":"6","author":"MB Sonbol","year":"2020","unstructured":"Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, et al. Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. JAMA Oncol. 2020;6:e204930.","journal-title":"JAMA Oncol"},{"key":"8735_CR11","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/liv.15953","volume":"44","author":"Y Qin","year":"2024","unstructured":"Qin Y, Han S, Yu Y, Qi D, Ran M, Yang M, et al. Lenvatinib in hepatocellular carcinoma: resistance mechanisms and strategies for improved efficacy. Liver Int. 2024;44:1808\u201331.","journal-title":"Liver Int"},{"key":"8735_CR12","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/mc.22126","volume":"54","author":"QZ Pan","year":"2015","unstructured":"Pan QZ, Pan K, Weng DS, Zhao JJ, Zhang XF, Wang DD, et al. Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. Mol Carcinog. 2015;54:598\u2013607.","journal-title":"Mol Carcinog"},{"key":"8735_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107139","volume":"89","author":"Q Zhu","year":"2020","unstructured":"Zhu Q, Pan QZ, Zhong AL, Hu H, Zhao JJ, Tang Y, et al. Annexin A3 upregulates the infiltrated neutrophil-lymphocyte ratio to remodel the immune microenvironment in hepatocellular carcinoma. Int Immunopharmacol. 2020;89:107139.","journal-title":"Int Immunopharmacol"},{"key":"8735_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/stem.1850","volume":"33","author":"QZ Pan","year":"2015","unstructured":"Pan QZ, Pan K, Wang QJ, Weng DS, Zhao JJ, Zheng HX, et al. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells. Stem Cells. 2015;33:354\u201366.","journal-title":"Stem Cells"},{"key":"8735_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.stemcr.2015.05.013","volume":"5","author":"M Tong","year":"2015","unstructured":"Tong M, Fung TM, Luk ST, Ng KY, Lee TK, Lin CH, et al. ANXA3\/JNK signaling promotes self-renewal and tumor growth, and its blockade provides a therapeutic target for hepatocellular carcinoma. Stem cell Rep. 2015;5:45\u201359.","journal-title":"Stem cell Rep"},{"key":"8735_CR16","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3892\/ol.2021.13095","volume":"22","author":"C Liu","year":"2021","unstructured":"Liu C, Li N, Liu G, Feng X. Annexin A3 and cancer. Oncol Lett. 2021;22:834.","journal-title":"Oncol Lett"},{"key":"8735_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4149\/neo_2014_033","volume":"61","author":"SY Yu","year":"2014","unstructured":"Yu SY, Li Y, Fan LQ, Zhao Q, Tan BB, Liu Y. Impact of Annexin A3 expression in gastric cancer cells. Neoplasma. 2014;61:257\u201364.","journal-title":"Neoplasma"},{"key":"8735_CR18","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3892\/or.2016.5251","volume":"37","author":"T Zhou","year":"2017","unstructured":"Zhou T, Li Y, Yang L, Liu L, Ju Y, Li C. Silencing of ANXA3 expression by RNA interference inhibits the proliferation and invasion of breast cancer cells. Oncol Rep. 2017;37:388\u201398.","journal-title":"Oncol Rep"},{"key":"8735_CR19","doi-asserted-by":"publisher","first-page":"e713","DOI":"10.1016\/j.clbc.2017.11.009","volume":"18","author":"JY Kim","year":"2018","unstructured":"Kim JY, Jung EJ, Park HJ, Lee JH, Song EJ, Kwag SJ, et al. Tumor-suppressing effect of silencing of Annexin A3 expression in breast cancer. Clin Breast Cancer. 2018;18:e713\u2013e9.","journal-title":"Clin Breast Cancer"},{"key":"8735_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/path.2429","volume":"217","author":"YF Liu","year":"2009","unstructured":"Liu YF, Xiao ZQ, Li MX, Li MY, Zhang PF, Li C, et al. Quantitative proteome analysis reveals Annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol. 2009;217:54\u201364.","journal-title":"J Pathol"},{"key":"8735_CR21","first-page":"4837","volume":"22","author":"L Yang","year":"2018","unstructured":"Yang L, Men WL, Yan KM, Tie J, Nie YZ, Xiao HJ. MiR-340-5p is a potential prognostic indicator of colorectal cancer and modulates ANXA3. Eur Rev Med Pharm Sci. 2018;22:4837\u201345.","journal-title":"Eur Rev Med Pharm Sci"},{"key":"8735_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-020-00219-2","volume":"5","author":"YCE Wan","year":"2020","unstructured":"Wan YCE, Liu J, Zhu L, Kang TZE, Zhu X, Lis J, et al. The H2BG53D oncohistone directly upregulates ANXA3 transcription and enhances cell migration in pancreatic ductal adenocarcinoma. Signal Transduct Target Ther. 2020;5:106.","journal-title":"Signal Transduct Target Ther"},{"key":"8735_CR23","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/2326-6066.CIR-23-0595","volume":"12","author":"L Xu","year":"2024","unstructured":"Xu L, Li W, Liu D, Cao J, Ge J, Liu X, et al. ANXA3-rich exosomes derived from tumor-associated macrophages regulate ferroptosis and lymphatic metastasis of laryngeal squamous cell carcinoma. Cancer Immunol Res. 2024;12:614\u201330.","journal-title":"Cancer Immunol Res"},{"key":"8735_CR24","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jhep.2018.05.034","volume":"69","author":"M Tong","year":"2018","unstructured":"Tong M, Che N, Zhou L, Luk ST, Kau PW, Chai S, et al. Efficacy of Annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. J Hepatol. 2018;69:826\u201339.","journal-title":"J Hepatol"},{"key":"8735_CR25","doi-asserted-by":"publisher","first-page":"G309","DOI":"10.1152\/ajpgi.00322.2019","volume":"319","author":"X Wan","year":"2020","unstructured":"Wan X, Guo D, Zhu Q, Qu R. microRNA-382 suppresses the progression of pancreatic cancer through the PI3K\/Akt signaling pathway by inhibition of Anxa3. Am J Physiol Gastrointest Liver Physiol. 2020;319:G309\u2013g22.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"8735_CR26","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.prp.2018.09.009","volume":"214","author":"J Li","year":"2018","unstructured":"Li J, Zhou T, Liu L, Ju YC, Chen YT, Tan ZR, et al. The regulatory role of Annexin 3 in a nude mouse bearing a subcutaneous xenograft of MDA-MB-231 human breast carcinoma. Pathol Res Pr. 2018;214:1719\u201325.","journal-title":"Pathol Res Pr"},{"key":"8735_CR27","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andre","year":"2019","unstructured":"Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929\u201340.","journal-title":"N Engl J Med"},{"key":"8735_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04206-5","volume":"12","author":"H Xu","year":"2021","unstructured":"Xu H, Chen K, Shang R, Chen X, Zhang Y, Song X, et al. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma. Cell Death Dis. 2021;12:920.","journal-title":"Cell Death Dis"},{"key":"8735_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","volume":"22","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22:489\u201398.","journal-title":"Lancet Oncol"},{"key":"8735_CR30","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/s41418-019-0421-7","volume":"27","author":"K Yuan","year":"2020","unstructured":"Yuan K, Xie K, Lan T, Xu L, Chen X, Li X, et al. TXNDC12 promotes EMT and metastasis of hepatocellular carcinoma cells via activation of beta-catenin. Cell Death Differ. 2020;27:1355\u201368.","journal-title":"Cell Death Differ"},{"key":"8735_CR31","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1080\/15548627.2019.1586250","volume":"15","author":"H Wu","year":"2019","unstructured":"Wu H, Lu XX, Wang JR, Yang TY, Li XM, He XS, et al. TRAF6 inhibits colorectal cancer metastasis through regulating selective autophagic CTNNB1\/beta-catenin degradation and is targeted for GSK3B\/GSK3beta-mediated phosphorylation and degradation. Autophagy. 2019;15:1506\u201322.","journal-title":"Autophagy"},{"key":"8735_CR32","first-page":"F79","volume":"1378","author":"CH Heldin","year":"1998","unstructured":"Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim et Biophys Acta. 1998;1378:F79\u2013113.","journal-title":"Biochim et Biophys Acta"},{"key":"8735_CR33","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.ejca.2011.05.007","volume":"47","author":"M Kudo","year":"2011","unstructured":"Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117\u201327.","journal-title":"Eur J Cancer"},{"key":"8735_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.","journal-title":"Vasc Cell"},{"key":"8735_CR35","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/HEP.0000000000000237","volume":"79","author":"AD Ladd","year":"2024","unstructured":"Ladd AD, Duarte S, Sahin I, Zarrinpar A. Mechanisms of drug resistance in HCC. Hepatology. 2024;79:926\u201340.","journal-title":"Hepatology"},{"key":"8735_CR36","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"Jin H, Shi Y, Lv Y, Yuan S, Ramirez CFA, Lieftink C, et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021;595:730\u20134.","journal-title":"Nature"},{"key":"8735_CR37","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.apsb.2022.11.023","volume":"13","author":"Y Liang","year":"2023","unstructured":"Liang Y, Min D, Fan H, Liu K, Tu J, He X, et al. Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer. Acta Pharmaceutica Sin B. 2023;13:1686\u201398.","journal-title":"Acta Pharmaceutica Sin B"},{"key":"8735_CR38","doi-asserted-by":"publisher","first-page":"8690","DOI":"10.1245\/s10434-023-14032-y","volume":"30","author":"S Wang","year":"2023","unstructured":"Wang S, Zeng X, Gui P, Xu S, Li Z, Chen D. LncRNA EBLN3P facilitates osteosarcoma metastasis by enhancing Annexin A3 mRNA stability and recruiting HuR. Ann Surg Oncol. 2023;30:8690\u2013703.","journal-title":"Ann Surg Oncol"},{"key":"8735_CR39","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.1038\/onc.2014.434","volume":"34","author":"J Chen","year":"2015","unstructured":"Chen J, Lan T, Zhang W, Dong L, Kang N, Zhang S, et al. Platelet-activating factor receptor-mediated PI3K\/AKT activation contributes to the malignant development of esophageal squamous cell carcinoma. Oncogene. 2015;34:5114\u201327.","journal-title":"Oncogene"},{"key":"8735_CR40","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1038\/onc.2013.472","volume":"33","author":"SM Yun","year":"2014","unstructured":"Yun SM, Yoon K, Lee S, Kim E, Kong SH, Choe J, et al. PPP1R1B-STARD3 chimeric fusion transcript in human gastric cancer promotes tumorigenesis through activation of PI3K\/AKT signaling. Oncogene. 2014;33:5341\u20137.","journal-title":"Oncogene"},{"key":"8735_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","volume":"30","author":"JA Fresno Vara","year":"2004","unstructured":"Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K\/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30:193\u2013204.","journal-title":"Cancer Treat Rev"},{"key":"8735_CR42","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997\u20131007.","journal-title":"N Engl J Med"},{"key":"8735_CR43","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"P Ghia","year":"2020","unstructured":"Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2849\u201361.","journal-title":"J Clin Oncol"},{"key":"8735_CR44","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","volume":"22","author":"MJ Matasar","year":"2021","unstructured":"Matasar MJ, Capra M, Ozcan M, LV F, Li W, Yanez E, et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22:678\u201389.","journal-title":"Lancet Oncol"},{"key":"8735_CR45","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28:2169\u201378.","journal-title":"Ann Oncol"},{"key":"8735_CR46","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.annonc.2020.12.009","volume":"32","author":"HY Yhim","year":"2021","unstructured":"Yhim HY, Kim T, Kim SJ, Shin HJ, Koh Y, Kim JS, et al. Combination treatment of copanlisib and gemcitabine in relapsed\/refractory PTCL (COSMOS): an open-label phase I\/II trial. Ann Oncol. 2021;32:552\u20139.","journal-title":"Ann Oncol"},{"key":"8735_CR47","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1200\/JCO.20.03433","volume":"39","author":"NH Fowler","year":"2021","unstructured":"Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA, et al. Umbralisib, a dual PI3Kdelta\/CK1epsilon inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol. 2021;39:1609\u201318.","journal-title":"J Clin Oncol"},{"key":"8735_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216996","volume":"597","author":"D Hu","year":"2024","unstructured":"Hu D, Cao J, Yu H, Ding N, Mi L, Ye Y, et al. PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4\/6 inhibitor palbociclib via PLK1 in B-cell lymphoma. Cancer Lett. 2024;597:216996.","journal-title":"Cancer Lett"},{"key":"8735_CR49","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41591-024-03076-6","volume":"30","author":"SM Horwitz","year":"2024","unstructured":"Horwitz SM, Nirmal AJ, Rahman J, Xu R, Drill E, Galasso N, et al. Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial. Nat Med. 2024;30:2517\u201327.","journal-title":"Nat Med"},{"key":"8735_CR50","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.annonc.2020.05.001","volume":"31","author":"HS Rugo","year":"2020","unstructured":"Rugo HS, Andre F, Yamashita T, Cerda H, Toledano I, Stemmer SM, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020;31:1001\u201310.","journal-title":"Ann Oncol"},{"key":"8735_CR51","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","volume":"32","author":"F Andre","year":"2021","unstructured":"Andre F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32:208\u201317.","journal-title":"Ann Oncol"},{"key":"8735_CR52","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1158\/1078-0432.CCR-20-4879","volume":"27","author":"P Sharma","year":"2021","unstructured":"Sharma P, Abramson VG, O\u2019Dea A, Nye L, Mayer I, Pathak HB, et al. Clinical and biomarker results from phase I\/II study of PI3K inhibitor alpelisib plus Nab-paclitaxel in HER2-negative metastatic breast cancer. Clin Cancer Res. 2021;27:3896\u2013904.","journal-title":"Clin Cancer Res"},{"key":"8735_CR53","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/S1470-2045(18)30905-7","volume":"20","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, et al. Olaparib and alpha-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019;20:570\u201380.","journal-title":"Lancet Oncol"},{"key":"8735_CR54","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1039\/D0SC01676D","volume":"11","author":"M Zhang","year":"2020","unstructured":"Zhang M, Jang H, Nussinov R. PI3K inhibitors: review and new strategies. Chem Sci. 2020;11:5855\u201365.","journal-title":"Chem Sci"},{"key":"8735_CR55","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","volume":"36","author":"D Juric","year":"2018","unstructured":"Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, et al. Phosphatidylinositol 3-kinase alpha-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol. 2018;36:1291\u20139.","journal-title":"J Clin Oncol"},{"key":"8735_CR56","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-025-02180-4","volume":"10","author":"N Gremke","year":"2025","unstructured":"Gremke N, Besong I, Stroh A, von Wichert L, Witt M, Elmshauser S, et al. Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs. Signal Transduct Target Ther. 2025;10:92.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08735-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08735-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08735-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:04:28Z","timestamp":1779167068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08735-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8735"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08735-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from all patients before sample collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ethics approval for the use of human tumor specimens was provided by the Internal Review and the Ethics Boards of the Sun Yat-Sen University Cancer Center (Approval No. G2022-172-01). The animal experiments were approved by the Institutional Animal Care and Use Committee of the Sun Yat-Sen University Cancer Center (Approval No. L102022022004A).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"478"}}